Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

UTHR

United Therapeutics Corp

Dec 12 • 04:00PM ET

493.99

+5.48 1.12 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: IJH VTI VB VBR VXF XMHQ MDY IBB XBI IJK

Scroll to Statements

Index	-	P/E	18.72	EPS (ttm)	26.39	Insider Own	3.54%	Shs Outstand	42.90M	Perf Week	0.96%
Market Cap	21.27B	Forward P/E	16.27	EPS next Y	30.36	Insider Trans	-37.19%	Shs Float	41.53M	Perf Month	7.03%
Enterprise Value	18.50B	PEG	1.77	EPS next Q	7.10	Inst Own	96.11%	Short Float	4.26%	Perf Quarter	22.54%
Income	1.27B	P/S	6.80	EPS this Y	11.61%	Inst Trans	-5.54%	Short Ratio	2.87	Perf Half Y	74.34%
Sales	3.13B	P/B	3.22	EPS next Y	10.42%	ROA	17.57%	Short Interest	1.77M	Perf YTD	40.00%
Book/sh	153.61	P/C	7.69	EPS next 5Y	9.20%	ROE	20.04%	52W High	492.62 0.28%	Perf Year	36.37%
Cash/sh	64.28	P/FCF	18.96	EPS past 3/5Y	34.80% -	ROIC	19.30%	52W Low	266.98 85.03%	Perf 3Y	78.28%
Dividend Est.	-	EV/EBITDA	11.57	Sales past 3/5Y	19.52% 14.71%	Gross Margin	88.59%	Volatility	1.98% 2.24%	Perf 5Y	280.05%
Dividend TTM	-	EV/Sales	5.91	EPS Y/Y TTM	17.16%	Oper. Margin	48.46%	ATR (14)	10.88	Perf 10Y	211.08%
Dividend Ex-Date	-	Quick Ratio	6.07	Sales Y/Y TTM	13.50%	Profit Margin	40.65%	RSI (14)	65.79	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	6.40	EPS Q/Q	12.12%	SMA20	2.81%	Beta	0.84	Target Price	526.09
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	6.76%	SMA50	8.07%	Rel Volume	0.80	Prev Close	488.51
Employees	1305	LT Debt/Eq	0.00	Earnings	Oct 29 BMO	SMA200	39.83%	Avg Volume	615.68K	Price	493.99
IPO	Jun 17, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.14% -1.64%	Trades		Volume	491,586	Change	1.12%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Underweight	$414
Sep-26-25	Initiated	RBC Capital Mkts	Outperform	$569
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight	$405
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125

Show Previous Ratings

Dec-11-25 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Dec-09-25 12:26PM	This Gold Stock Hits A High, With Miner Poised For Huge Swing To Profit (Investor's Business Daily)
09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
11:30AM	Loading…
Dec-05-25 11:30AM	Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
11:20AM	Can Merck's New Products Aid Growth as Keytruda LOE Test Looms? (Zacks)
Dec-03-25 07:19AM	Flurry of Bullish Inflows Sends United Therapeutics Higher (FX Empire)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-20-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Nov-19-25 10:52AM	Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study (Zacks)
Nov-12-25 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-09-25 11:02PM	3 Reasons Investors Love United Therapeutics (UTHR) (StockStory)
09:40AM	Loading…
Nov-05-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
12:35AM	The 5 Most Interesting Analyst Questions From United Therapeutics's Q3 Earnings Call (StockStory)
Nov-04-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
07:00AM	United Therapeutics Corporation to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 07:00AM	United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease (Business Wire)
Oct-30-25 03:48PM	United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:40AM	MKKGY vs. UTHR: Which Stock Is the Better Value Option? (Zacks)
01:38AM	UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook (StockStory)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily) +9.63%
01:11PM	Why Is United Therapeutics (UTHR) Stock Soaring Today (StockStory)
11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:51AM	United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short (Investor's Business Daily)
07:40AM	United Therapeutics (UTHR) Beats Q3 Earnings Estimates (Zacks)
06:48AM	Loading…
06:48AM	United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
06:43AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results (Business Wire)
Oct-27-25 11:17PM	United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 10:05AM	Merck's Non-Oncology Drugs Q3 Performance: What to Expect (Zacks)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-22-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-16-25 03:51PM	Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case (Insider Monkey)
Oct-15-25 07:00AM	United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 (Business Wire)
Oct-13-25 07:00AM	United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting (Business Wire)
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Sep-30-25 04:38PM	Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals (Zacks)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-19-25 11:53AM	Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE? (Zacks)
07:00AM	United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis (Business Wire)
12:46AM	1 Momentum Stock to Target This Week and 2 We Brush Off (StockStory)
12:03AM	3 Big Reasons to Love United Therapeutics (UTHR) (StockStory)
Sep-16-25 07:00AM	United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum (Business Wire)
Sep-12-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress (Business Wire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-10-25 02:46PM	United Therapeutics Price Strength Rating Jumps; Stock Soared 33% Last Week (Investor's Business Daily)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
08:52AM	Pharma, Opendoor, Tesla: Trending Stocks (Yahoo Finance Video)
06:30AM	Lung Disease Breakthrough Boosts United Therapeutics and its Rivals (The Daily Upside)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily) +32.83%
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
07:00AM	United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Aug-29-25 11:30AM	Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report? (Zacks)
07:00AM	United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-13-25 12:05AM	5 Insightful Analyst Questions From United Therapeutics's Q2 Earnings Call (StockStory)
Aug-12-25 11:40PM	UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty (StockStory)
04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
Aug-11-25 04:15PM	3D Systems Reports Second Quarter 2025 Financial Results (GlobeNewswire)
11:32AM	Merck's Narrowed 2025 Sales View: What it Means After Q2 Results? (Zacks)
Aug-01-25 07:00AM	United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program (Business Wire) +7.13%
Jul-31-25 10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
Jul-30-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks) -5.25%
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics (Zacks)
07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
06:46AM	United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates (StockStory)
06:36AM	United Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results (Business Wire)
Jul-28-25 11:13PM	What To Expect From United Therapeutics's (UTHR) Q2 Earnings (StockStory)
10:00AM	Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline (Zacks)
02:07AM	Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT (Insider Monkey)
Jul-25-25 10:42PM	United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial (Insider Monkey)
Jul-24-25 09:50AM	United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily)
Jul-23-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jul-21-25 06:32PM	United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag (Insider Monkey)
Jul-18-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jul-16-25 07:00AM	United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025 (Business Wire)
Jul-15-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jul-11-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Jul-10-25 11:26PM	UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) (Insider Monkey)
Jul-09-25 12:33AM	1 Value Stock with Impressive Fundamentals and 2 to Turn Down (StockStory)
Jul-07-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jul-04-25 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-03-25 08:30AM	MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE (Zacks)
Jul-02-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jun-28-25 04:16AM	United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study (Insider Monkey)
Jun-26-25 09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Jun-25-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
07:40AM	5 Must-Read Analyst Questions From United Therapeutics's Q1 Earnings Call (StockStory)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MALCOLM JAN	Director	Dec 11 '25	Sale	482.98	50	24,149	470	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Option Exercise	146.03	11,000	1,606,330	47,781	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Sale	484.67	11,000	5,331,316	36,781	Dec 12 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Sale	490.70	4,000	1,962,783	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Sale	483.97	4,000	1,935,879	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 12 '25	Proposed Sale	490.70	4,000	1,962,783		Dec 12 04:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 11 '25	Proposed Sale	483.97	4,000	1,935,879		Dec 11 04:10 PM
PAUL MAHON	Officer	Dec 11 '25	Proposed Sale	484.67	11,000	5,331,316		Dec 11 04:06 PM
Mesa Nilda	Director	Dec 09 '25	Sale	481.63	187	90,065	5,286	Dec 10 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Sale	480.05	4,000	1,920,191	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Sale	478.30	4,000	1,913,184	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 10 '25	Proposed Sale	480.05	4,000	1,920,190		Dec 10 03:52 PM
NILDA MESA	Director	Dec 09 '25	Proposed Sale	481.63	187	90,065		Dec 09 06:01 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Dec 09 04:54 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Sale	478.60	21,000	10,050,597	8,142	Dec 09 04:54 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Option Exercise	244.05	22,500	5,491,040	14,625	Dec 09 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Sale	478.58	22,500	10,768,000	0	Dec 09 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 09 '25	Proposed Sale	478.30	4,000	1,913,184		Dec 09 03:47 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 08 '25	Proposed Sale	484.23	4,000	1,936,936		Dec 08 06:25 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Sale	484.23	4,000	1,936,936	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Sale	483.28	4,000	1,933,120	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 03 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 04 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 04 '25	Sale	480.01	4,000	1,920,043	130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 03 '25	Sale	475.27	4,000	1,901,087	130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 05 '25	Proposed Sale	483.28	4,000	1,933,120		Dec 05 04:18 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 04 '25	Proposed Sale	480.01	4,000	1,920,043		Dec 04 03:30 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 03 '25	Proposed Sale	475.27	4,000	1,901,088		Dec 03 03:21 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 01 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Dec 02 04:32 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 01 '25	Sale	479.99	21,000	10,079,696	8,142	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 01 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 02 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 01 '25	Sale	481.93	4,000	1,927,703	130	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 02 '25	Sale	481.29	4,000	1,925,143	130	Dec 02 04:32 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 01 '25	Option Exercise	127.65	22,500	2,872,226	14,625	Dec 02 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 01 '25	Sale	479.91	22,500	10,798,079	0	Dec 02 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 02 '25	Proposed Sale	481.29	4,000	1,925,143		Dec 02 03:58 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 01 '25	Proposed Sale	481.93	4,000	1,927,703		Dec 01 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 26 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 01 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 28 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 01 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 28 '25	Sale	487.64	4,000	1,950,550	130	Dec 01 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 26 '25	Sale	485.05	4,000	1,940,204	130	Dec 01 04:31 PM
JAMES EDGEMOND	Officer	Dec 01 '25	Proposed Sale	486.00	105,000	51,030,000		Dec 01 04:23 PM
Michael Benkowitz	Officer	Dec 01 '25	Proposed Sale	486.00	112,500	54,675,000		Dec 01 04:19 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 28 '25	Proposed Sale	487.64	4,000	1,950,550		Nov 28 04:08 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 24 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Nov 26 04:31 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 24 '25	Sale	473.64	21,000	9,946,544	8,142	Nov 26 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 24 '25	Option Exercise	137.07	22,500	3,084,146	12,000	Nov 26 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 24 '25	Sale	473.66	22,500	10,657,280	0	Nov 26 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 26 '25	Option Exercise	135.42	11,000	1,489,620	47,781	Nov 26 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 26 '25	Sale	486.06	11,000	5,346,701	36,781	Nov 26 04:30 PM
PAUL MAHON	Officer	Nov 26 '25	Proposed Sale	486.06	11,000	5,346,701		Nov 26 04:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 26 '25	Proposed Sale	485.05	4,000	1,940,204		Nov 26 03:45 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 24 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 25 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 25 '25	Sale	475.33	4,000	1,901,305	130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 24 '25	Sale	470.78	4,000	1,883,114	130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 25 '25	Proposed Sale	475.33	4,000	1,901,305		Nov 25 03:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 24 '25	Proposed Sale	470.78	4,000	1,883,114		Nov 24 03:46 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 20 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 21 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 20 '25	Sale	478.38	4,000	1,913,524	130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 21 '25	Sale	474.64	4,000	1,898,558	130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 21 '25	Proposed Sale	474.64	4,000	1,898,558		Nov 21 03:59 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 18 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 19 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 19 '25	Sale	474.58	4,000	1,898,336	130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 18 '25	Sale	472.76	4,000	1,891,037	130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 20 '25	Proposed Sale	478.38	4,000	1,913,524		Nov 20 03:00 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 19 '25	Proposed Sale	474.58	4,000	1,898,336		Nov 19 02:40 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 17 '25	Option Exercise	139.13	22,500	3,130,504	14,625	Nov 18 04:36 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 17 '25	Sale	470.43	22,500	10,584,756	0	Nov 18 04:36 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 17 '25	Option Exercise	146.03	21,000	3,066,630	18,806	Nov 18 04:35 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 17 '25	Sale	470.36	21,000	9,877,535	8,118	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 14 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 17 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 17 '25	Sale	467.55	4,000	1,870,192	130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 14 '25	Sale	462.94	4,000	1,851,774	130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 18 '25	Proposed Sale	472.76	4,000	1,891,038		Nov 18 04:00 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 17 '25	Proposed Sale	467.55	4,000	1,870,192		Nov 17 04:10 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 14 '25	Proposed Sale	462.94	4,000	1,851,774		Nov 14 03:00 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 12 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 13 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 13 '25	Sale	728.96	4,000	2,915,859	130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 12 '25	Sale	460.00	4,000	1,839,996	130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 13 '25	Proposed Sale	463.35	4,000	1,853,409		Nov 13 04:37 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 13 '25	Option Exercise	135.42	11,000	1,489,620	47,781	Nov 13 04:33 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 13 '25	Sale	464.76	11,000	5,112,335	36,781	Nov 13 04:33 PM
PAUL MAHON	Officer	Nov 13 '25	Proposed Sale	464.76	11,000	5,112,335		Nov 13 04:04 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 10 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Nov 12 05:14 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 10 '25	Sale	452.07	22,500	10,171,683	0	Nov 12 05:14 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 10 '25	Option Exercise	146.03	21,000	3,066,630	29,118	Nov 12 05:13 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 10 '25	Sale	452.07	21,000	9,493,483	8,118	Nov 12 05:13 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 12 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UTHR

United Therapeutics Corp

Upgrade your FINVIZ experience